These data propose GRK2 as a possible therapeutic target for metabolic disorders and that its inhibition may have therapeutic effects on all IRES related conditions, providing a new therapeutic approach for the treatment of T2DM [14,15]. This evidence concerns the gene GRK2 and metabolic disease.